BeyondSpring Inc. (BYSI, Financial) experienced a notable stock price increase of 5.39%, reaching $2.54 per share. The trading volume was 20,920 shares, with a turnover rate of 0.05% and a volatility of 10.37%. Recent financial reports indicate that the company's revenue reached $1,000,000, with a net loss of $7.26 million, resulting in an earnings per share (EPS) of -$0.19 and a price-to-earnings (P/E) ratio of -6.29.
Currently, no institutional ratings or recommendations (buy, hold, sell) are available for BYSI. Within the biotechnology sector, where BYSI operates, the average decline was 1.17%. Specific stocks in this industry showed significant variations, with Tc Biopharm (Holdings) Plc, Coeptis Therapeutics Holdings Inc., and Bioatla, Inc. seeing notable gains. In contrast, Aditxt, Inc., Windtree Therapeutics, Inc., and Tc Biopharm (Holdings) Plc were particularly active, with turnover rates of 1252.25%, 70.02%, and 57.99%, respectively.
Stocks with substantial volatility included Pasithea Therapeutics Corp, Tevogen Bio Holdings Inc., and Apollomics Inc., with volatility rates of 145.55%, 70.19%, and 60.44%, respectively.
BeyondSpring Inc. is engaged in clinical-stage biopharmaceutical activities, focusing on cancer treatments and immuno-oncology drugs. It operates through two segments: the Plinabulin pipeline and the TPD platform.
